NASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Price, News & Analysis $69.12 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$67.88 -1.24 (-1.80%) As of 05/22/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About BridgeBio Pharma Stock (NASDAQ:BBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BridgeBio Pharma alerts:Sign Up Key Stats Today's Range$68.42▼$71.7450-Day Range$64.68▼$77.9352-Week Range$31.77▼$84.94Volume1.83 million shsAverage Volume3.36 million shsMarket Capitalization$13.54 billionP/E RatioN/ADividend YieldN/APrice Target$88.90Consensus RatingModerate Buy Company Overview BridgeBio Pharma, Inc. is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside. BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies. Its lead programs address rare and serious conditions such as transthyretin amyloidosis, achondroplasia, phenylketonuria and select oncology indications driven by genetic mutations. Among its most advanced candidates are acoramidis (formerly AG10), an oral TTR stabilizer for cardiomyopathy, and infigratinib, an FGFR inhibitor for cholangiocarcinoma and other cancers with FGFR alterations. Since inception, BridgeBio has expanded its clinical and research activities across North America, Europe and Asia, collaborating with regulatory agencies and academic centers to advance its programs worldwide. The company maintains research hubs in major biotech clusters and leverages strategic partnerships to support global trials and regulatory submissions, reinforcing its commitment to addressing unmet medical needs on a multinational scale. Neil Kumar serves as President and Chief Executive Officer, bringing extensive experience in biotech entrepreneurship and drug development. BridgeBio’s leadership team combines expertise in translational science, regulatory affairs and commercial strategy, supported by a network of investors and collaborators. This multidisciplinary approach underpins the company’s mission to translate genetic insights into safe and effective therapies for patients facing rare and life-threatening diseases.AI Generated. May Contain Errors. Read More BridgeBio Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreBBIO MarketRank™: BridgeBio Pharma scored higher than 70% of companies evaluated by MarketBeat, and ranked 232nd out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on no strong buy ratings, 23 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialBridgeBio Pharma has a consensus price target of $88.90, representing about 28.6% upside from its current price of $69.12.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BridgeBio Pharma are expected to grow in the coming year, from ($2.27) to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -18.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -18.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BridgeBio Pharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.30% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 7.59.Change versus previous monthShort interest in BridgeBio Pharma has recently increased by 5.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.47 News SentimentBridgeBio Pharma has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for BridgeBio Pharma this week, compared to 9 articles on an average week.Search Interest21 people have searched for BBIO on MarketBeat in the last 30 days. This is an increase of 320% compared to the previous 30 days.MarketBeat Follows10 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 900% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,364,492.00 in company stock.Percentage Held by Insiders14.23% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Pharma's insider trading history. Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBIO Stock News HeadlinesBridgeBio Pharma (BBIO) Gets a Hold from CitiMay 22 at 9:27 AM | theglobeandmail.comInsider Selling: BridgeBio Pharma (NASDAQ:BBIO) Director Sells $671,500.00 in StockMay 22 at 5:01 AM | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.May 25 at 1:00 AM | Banyan Hill Publishing (Ad)Thomas Trimarchi Sells 13,651 Shares of BridgeBio Pharma (NASDAQ:BBIO) StockMay 21, 2026 | americanbankingnews.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 21, 2026 | americanbankingnews.comInsider Selling: BridgeBio Pharma (NASDAQ:BBIO) Director Sells 10,000 Shares of StockMay 20, 2026 | insidertrades.comBridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 SharesMay 12, 2026 | insidertrades.comMaricel Apuli Sells 2,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) StockMay 5, 2026 | insidertrades.comSee More Headlines BBIO Stock Analysis - Frequently Asked Questions How have BBIO shares performed this year? BridgeBio Pharma's stock was trading at $76.49 at the beginning of 2026. Since then, BBIO shares have decreased by 9.6% and is now trading at $69.12. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) posted its quarterly earnings data on Thursday, May, 7th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.70) by $0.14. BridgeBio Pharma's revenue was up 66.8% compared to the same quarter last year. Read the conference call transcript. When did BridgeBio Pharma IPO? BridgeBio Pharma (BBIO) raised $308 million in an initial public offering on Thursday, June 27th 2019. The company issued 20,500,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR served as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. Who are BridgeBio Pharma's major shareholders? Top institutional shareholders of BridgeBio Pharma include Janus Henderson Group PLC (6.73%), The Manufacturers Life Insurance Company (1.01%), Pictet Asset Management Holding SA (0.71%) and Principal Financial Group Inc. (0.68%). Insiders that own company stock include Global Investors Lp Viking, Genetic Disorder LP Kkr, Charles J Homcy, Frank Mccormick, Neil Kumar, Thomas Trimarchi, Maricel Apuli, Brian C Stephenson, Andrew Lo, Andrea Ellis, Ronald J Daniels, Randal W Scott and Hannah Valantine. View institutional ownership trends. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2026Today5/25/2026Jefferies Global Healthcare Conference 20266/04/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BBIO's financial health is in the Green zone, according to TradeSmith. BBIO has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - GENERIC DRG Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BBIO CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees400Year Founded2014Price Target and Rating Average Price Target for BridgeBio Pharma$88.90 High Price Target$110.00 Low Price Target$49.00 Potential Upside/Downside+28.6%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage25 Analysts Profitability EPS (Trailing Twelve Months)($3.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$724.93 million Net Margins-124.42% Pretax Margin-125.78% Return on EquityN/A Return on Assets-65.81% Debt Debt-to-Equity RatioN/A Current Ratio1.52 Quick Ratio1.48 Sales & Book Value Annual Sales$502.08 million Price / Sales26.96 Cash FlowN/A Price / Cash FlowN/A Book Value($11.58) per share Price / Book-5.97Miscellaneous Outstanding Shares195,860,000Free Float167,990,000Market Cap$13.54 billion OptionableOptionable Beta1.02 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:BBIO) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
